Why the study?
Does an experimental inactivated CA16 vaccine induce a sustained immune response in mice and monkeys?
Does an experimental inactivated CA16 vaccine induce a sustained immune response in mice and monkeys?
An experimental inactivated CA16 vaccine demonstrated sustained immunogenicity and cross-neutralizing activity in mice and monkeys, supporting its potential as a vaccine candidate for hand, foot, and mouth disease.
Sustained immunogenicity in animal models supports advancing CA16 vaccine candidate; leaves open human translation and efficacy.
The coxsackie A16 virus (CA16), along with enterovirus 71 (EV71), is a primary pathogen that causes hand, foot, and mouth disease (HFMD). To control HFMD, CA16, and EV71 vaccines are needed. In this study, an experimental inactivated CA16 vaccine was prepared using human diploid cells, and the vaccine's immunogenicity was analyzed in mice and rhesus monkeys. The results showed that the neutralizing antibody was developed in a dose-dependent manner, and was sustained for 70 days with an average GMT (geometric mean titer) level of 80 to 90 in immunized mouse and for 56 days with GMT of higher than 300 in monkeys. The neutralizing antibody had a cross-neutralizing activity against different viral strains (genotype A and B), and the specific IFN-γ-secreting cell response was activated by these virus strains in an ELISPOT assay. This study provides evidence for the potential use of inactivated CA16 as a candidate for use in vaccines.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2014) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: